Guideline vulvovaginal candidosis (2010) of the german society for gynecology and obstetrics, the working group for infections and infectimmunology in gynecology and obstetrics, the german society of dermatology, the board of german dermatologists and the german speaking mycological society

Mycoses

Volumn 55, Issue SUPPL. 3, 2012, Pages 1-13

  Mendling, W ^a   Brasch, J ^b  

^a VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; BORIC ACID; CICLOPIROXOLAMINE; CLOTRIMAZOLE; ECONAZOLE; ESTROGEN; FENTICONAZOLE NITRATE; FLUCONAZOLE; FLUCYTOSINE; GLUCOSE; HOST FACTOR; IMIDAZOLE; ITRACONAZOLE; MICONAZOLE NITRATE; NATAMYCIN; NYSTATIN; POLYENE; POSACONAZOLE; SERTACONAZOLE; TERCONAZOLE; TIOCONAZOLE; TRIAZOLE;

ALLERGY; ANAMNESIS; ARTICLE; BURN; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; DERMATOLOGIST; DIABETIC PATIENT; DIAPER DERMATITIS; DNA POLYMORPHISM; ESTROGEN BLOOD LEVEL; FEMALE; FIRST TRIMESTER PREGNANCY; FUNGAL COLONIZATION; FUNGAL VIRULENCE; FUNGUS CULTURE; GENITAL PRURITUS; GERMANY; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; MEDICAL SOCIETY; MENTAL STRESS; NONVIRAL GENE DELIVERY SYSTEM; PATHOGENICITY; PH; PHASE CONTRAST MICROSCOPY; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; RECURRENT DISEASE; SACCHAROMYCES CEREVISIAE; SEXUAL BEHAVIOR; SKIN REDNESS; THIRD TRIMESTER PREGNANCY; THRUSH; UNSPECIFIED SIDE EFFECT; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINAL BURNING SENSATION; VAGINAL DELIVERY; VAGINAL PRURITUS; VIRUS HEPATITIS; VULVOVAGINITIS; YEAST;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, VULVOVAGINAL; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; SACCHAROMYCES CEREVISIAE;

EID: 84860238211     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2012.02185.x     Document Type: Article

References (140)

1. Abrams P, Khoury S, Grant A. Evidence - based medicine overview over the main steps for developing and grading guideline recommendations. Prog Urol 2007; 17: 681-4.
2. Anderson MR, Klink K, Cohrsson A. Evaluation of vaginal complaints. JAMA 2004; 291: 1368-79.
3. Auger P, Joly J. Microbial flora associated with Candida albicans vulvovaginitis. Am J Obstet Gynecol 1980; 55: 397-401.
4. Auler ME, Morreiva D, Rodriguez FF, Abr Ao MS, Margavido PF, Matsumoto FE, Silva BC, Schneider RP, Paula CR. Biofilm formation on intrauterine devices in patients with recurrent vulvovaginal candidiasis. Med Mycol 2010; 48: 211-6.
5. Babula O, Lazdane G, Kroica J, Linhares JM, Ledger WJ, Witkin SS. Frequency of interleukin - 4 (IL - 4) - 589 gene polymorphism and vaginal concentrations of IL - 4, nitric oxide, and mannosebinding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005; 40: 1258-62.
6. Beigi RH, Meyn LA, Moore DM, Krohn MA, Hillier SL. Vaginal yeast colonization in nonpregnant women: A longitudinal study. Obstet Gynecol 2004; 104: 926-30.
7. de Bernardis F, Agatensi L, Ross IK, et al. Evidence for a role for secretory asparatate proteinase of Candida albicans in vulvovaginal candidosis. J Infect Dis 1990; 161: 1276-83.
8. de Bernardis F, Boccanera M, Cassone A. The role of immunity against vaginal Candida infection. In: Fidel PL, Huffnagle GB (eds.) Fungal immunity: From an Organ perspective. Springer, Heidelberg New York 2005, pp 345-55.
9. Birkner V Essers M, Bühring M, Koldovsky U, Mendling W. Randomisierte 3-armige, offene, kontrollierte, klinische Therapiestudie zur Behandlung der chronisch-rezidivierenden vaginalen Kandidose mit einer systematischen apparativen Heliotherapie im Vergleich zu einer antimykotischen Standardtherapie und einer Vakzinationsbehandlung mit Gynatren. Mycoses 2005; 48(5): 310.
10. Bisshop MPJM, Merkus JMWM, Schleygrond H, van Cutsem J. Co-treatment of the male partner in vaginal candidosis: a double-blind randomised controlled-study. Br J Obstet Gynecol 1986; 93: 79-81.
11. Blaschke- Hellmessen R. Subpartale Übertragung von Candida und ihre Konsequenzen. Mycoses 1998; 41(Suppl. 2): 31-6.
12. Blaschke- Hellmessen R. Epidemiologische Untersuchungen zum Vorkommen von Hefepilzen bei Kindern und deren Müttern. Mykosen 1968; 611-6.
13. Bohanna NJ. Treatment of vulvovaginal candidiasis in patients with diabetes. Diabetes care 1998; 21: 451-6.
14. Bond CM, Watson MC, Grampian Evidence Based Community Pharmacy Guidelines Group. The development of evidence-based guidelines for the over-the-counter treatment of vulvovaginal candidiasis. Pharm World Sci 2003; 25: 177-81.
15. Buch A, Skytte-Christensen E. Treatment of vaginal candidosis with natamycin and effect of treating the partner at the same time. Acta Obstet Gynecol Scand 1982; 61: 393-6.
16. Cassone A. Immunization against Candida albicans vaginitis. Mycoses 2009; 52: 395.
17. Cassone A, de Bernardis F, Mondell F, Ceddia T, Agatensil Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Inf Dis 1987; 156: 777-82.
18. Cassone A, de Bernardis F, Torososantucci A. An outline of the role of anti-candida antibodies within the context of passive immunization and protection from candidiasis. Curr Mol Med 2005; 5: 377-82.
19. Cauwenberg G. International experience with Ketoconazole in vaginal candidosis. In: Eliot BW (ed) Oral therapy in vaginal candidosis. Medicine Publishing Foundation Oxford 1984.
20. Cetin M, Ocak S, Gungoren A, Hakverdi AU. Distribution of Candida species in women with vulvovaginal symptoms and their association with different ages and contraceptive methods. Scand J Infect Dis. 2007; 7: 584-8.
21. Chassot F, Negri MF, Swidsinski AF, Donati L, Peralta RM, Swidsinski S, Consolavo ME. Can intrauterine contraceptive devices be a Candida albicans reservoir? Contraception 2008; 77: 355-9.
22. Chaim W, Foxman B, Sobel JD. Association of recurrent vaginal Candidiasis and secretory ABO and Lewis phenotype. J Inf Dis 1997; 176: 828-30.
23. Cohen L. Is more than one application of an antifungal necessary in the treatment of an acute vaginal candidosis? Am J Obstet Gynecol 1985; 152: 961-4.
24. Corsello S, Spinillo A, Osnengo G, et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 2003; 110: 66-72.
25. Czeizel M, T., M Rockenbauer. No Teratogenic Effect after Clotrimazole Therapy during Pregnancy. Epidemiology 1999; 10: 437-40.
26. Czeizel AE, Fladung B, Varga P. Preterm birth reduction after clotrimazole treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 116: 157-63.
27. Czeizel AE, Puho EH, Kazu Z. The use of data set of the Hungarian case - control surveillance of congenital abnormalities for evaluation of birth outcomes beyond birth defects. Centr Eur J Public Health 2007; 15: 147-53.
28. Davidson F, Mould RF. Recurrent vaginal candidosis in women and the effect of intermittent prophylactic treatment. BJ Vener Dis 1978; 54: 176-83.
29. Davidson F, Oates JK. The pill does not cause thrush. Brit J Obstet Gynecol 1985; 92: 1265.
30. Dennerstein GJ, Ellis DH. Oestrogen, glycogen and vaginal candidiasis. Austr. NZ J Obstet Gynecol 2001; 41: 326-8.
31. Donders G. We, specialists in vulvovaginitis. Am J Obstet Gynecol 2001; 184: 248.
32. Donders G, Babula O, Bellen G, Linhares IM, Witkin SS. Mannose-bindling lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG. 2008; 115(10): 1223-31.
33. Donders G, Bellen G, Byttebier G, et al. Individualized decreasing dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol 2008; 199(6): 613.
34. Donders G, Prenen H, Verbeke G, Reybrouck R. Impaired tolerance for glucose in women with recurrent vaginal candidiasis. Am J Obstet Gynecol 2002; 187: 989-93.
35. Eckert Hawes SE, et al. Vulvovaginal Candidiasis: Clinical Manifestations, Risk Factors, Management Algorithm. Gynecol 1998; 92: 757-65.
36. Ehrström SM, Kornfeld D, Thuresson J, Rylander E. Signs of chronic stress in women with recurrent candida vulvovaginitis. Am J Obstet Gynecol 2005; 193: 1376-81.
37. Falagas ME, Betsi GI, Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. A Antimicrob Chemother. 2006; 58(2): 266-72.
38. Farrell SM, Hawkins DF, Ryder TT. Scanning electron microscope study of Candida albicans, invasion of cultural human cervical epithelial cells. Sabouraudia 1983; 25: 251-4.
39. Ferris GD, Nyirjesy P, Sobel JD, Soper D, Pavlitic A, Litaker MS. Over-the-counter antifungal drug misuse associated with patient diagnosed vulvovaginal candidosis. Obstet Gynecol 2002; 99: 419-25.
40. Fidel PL Jr. Immunity in vaginal candidiasis. Curr Opin Infect Dis 2005; 18: 107-11.
41. Fidel PL Jr. Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999; 12: 80-96.
42. Fong JW. The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with chronic recurrent vaginal candidiasis. Genitourin Med 1992; 68: 374-7.
43. Foxman B. The epidemiology of vulvovaginal candidiasis: risk factors. Am J Public Health 1990; 80: 329-331.
44. Gaspard U, Scheen A, et al. Randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception 2003; 67: 423-9.
45. Geraldo P, Neuer A, Korneeva IL, Ribeiro-Filho A, Simoes JA, Witkin SS. Vaginal heat shock protein expression in symptom-free women with history of recurrent vulvovaginitis. Am J Obstet Gynecol 1999; 180: 524-9.
46. Ghannoum MA, Abu-El Teen. Pathogenecity determinants of Candida. Mycoses 1990; 33: 265-82.
47. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 2000; 13: 122-43.
48. Golz R, Mendling W. Candidosis of the prostate. Rare form of endomycosis. Mycoses 1991; 34: 381-4.
49. Goswami R, Dadhwal V, Tejaswi S, et al. Species-specific prevalence of vaginal candidiasis amoung patients with diabetes mellitus and its relation to their glycaemic status. J Infect Dis 2000; 41: 162-6.
50. Goswami D, Goswami R, Banerjee U, et al. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J Infect 2006; 52: 111-7.
51. Hay PH, Czeizel AE. Asymptomatic trichomonas and candida colonization and pregnancy outcome. Best Pract Res Clin Obstet Gynecol 2007; 21(3): 403-9.
52. Hilton E, Isenberg HD, Alperstein P, et al. Ingestion of yoghourt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992; 116: 353-7.
53. Hoffstetter SE, Barr S, LeFevre C, Leong FC, Leet T. Self-reported yeast symptoms compared with clinical wet mount analysis and vaginal yeast culture in a specialty clinic setting. J Reprod Med. 2008; 53(6): 402-6.
54. Ip WK, Lan YL. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in Phagocytosis by human dendritic cells. J Inf Dis 2004; 190: 632-40.
55. Ismail A, Lupan DM. Utilisation of siderophores by Candida albicans. Mycopath 1986; 96: 109-13.
56. Jeavons HS. Prevention and treatment of vulvovaginal candidosis using exogenous lactobacilli. J Obstet Gynecol Neonatal Nurs 2003; 32: 287-96.
57. Kiss H, Petricevicz L, Husslein P. Prospective randomised controlled trial of an infection screening program to reduce the rate of preterm delivery. BMJ 2004; 329: 371-5.
58. Koldowsky H, Kariger U, Mendling W. Herstellung eines autologen membrangebundenen Candida-Antigens und in-vitro-Untersuchungen zu seinen immunologischen Reaktionen. In Metzner G, Weissenbacher ER (Hrsg.) Candida-Infektionen des weiblichen Genitaltraktes. Medifact München 1999, 25-32.
59. Kunzelmann V, Tietz HJ, Roßner D, Czaika V, Hopp M, Schmalreck A, Sterry W. Voraussetzungen für eine effektive Therapie chronisch rezidivierender Vaginalkandidosen. Mycoses 1996; 39(Suppl. 1): 65-72.
60. Lattif AA, Prasard R, et al. The glyzolate cycle enzyme activities in the pathogenitic isolates of Candida albicans obtained from HIV/AIDS, diabetic and burn patients. Mycoses 2006; 49: 85-9.
61. Ledger WJ, Polaseczky MM, Yih MC, Jeremias J, Tolbert V, Witkin SS. Difficulties in the diagnosis of Candida vaginitis. Inf Dis Clin Bact 2000; 9: 66-9.
62. Leon de E, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type I and type 2 diabetes. BMC Infect Dis 2002; 2: 1-6.
63. Li J, Fan SR, Liu XP, et al. Biased genotype distributions of Candida albicans strains associated with vulvovaginal candidosis and candidal balanoposthitis in China. Clin Infect Dis, 2008; 9: 1119-25.
64. Loeffler W. Terminologie der Humanmykosen. Mykosen 1983; 26(7): 346.
65. Lowe NK, Neal JL, Ryan-Wenger NA. Accuracy of the clinical diagnosis of vaginitis compared with a DNA probe laboratory standard. Obstet Gynecol 2009; 113: 89-95.
66. Mailänder-Sanchez D, Wagener I, Schaller M. Characterization of the protective immunmodulation of probiotic bacteria in localized candidiasis. Mycoses 2009; 52: 396.
67. Martinez RC, Seney SL, Summers KL, Nomitzo A, de Martinis FC, Reid G. Effect of Lactobacillus rhamnosus GR - 1 and Lactobacillus reuteri RC - 14 on the ability of Candida albicans to infect cells and induce inflammation. Microbiol Immunol 2009; 53: 487-95.
68. Mathema B, Cross E, Dun E, et al. Prevalence of vaginal colonization by drug-resistent Candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Inf Dis 2001; 33: E-23.
69. Meinhof W. Die Salzsäure-Toleranz von Candida albicans. Mykosen 1974; 17: 339-47.
70. Mendling W. Die Torulopsidose in der Frauenheilkunde, Geburtsh/Frauenheilk 1984; 44: 583-6.
71. Mendling W. Azoles in the therapy of vaginal candidosis. In: Berg D, Plempel M (eds) Sterol biosynthesis inhibitors. Ellis Horwood, Chichester 1988, pp 480-506.
72. Mendling W, Koldovsky U. Investigations by cell-mediated immunologic tests of therapeutic trials with thymopentin in vaginal mycoses. Inf Dis Obstet Gynecol 1996; 4: 225-31.
73. Mendling W, Gutschmidt J, Gantenberg R, Andrade P, Schönian G. Vergleich der Stammspezifität von Hefepilzen verschiedener Lokalisationen bei Frauen mit Vaginalcandidosen. Mycoses 1998; 41(Suppl. 2): 22-5.
74. Mendling W, Krauss C, Fladung B. A clinical multi-center-study comparing afficacy and tolerability of topical combination therapy with Clotrimazole (Canesten, two formats) with oral single dose fluconazole (Diflucan) in vulvovaginal mycoses. mycoses 2004; 47: 136-42.
75. Mendling W, Niemann D, Tintelnot K. Vaginal Colonisation with Candida Species with Special Focus on Candida dubliniensis A. Prospective Study. Geburtsh Frauenheilk 2007; 67: 1132-7.
76. Mendling W, Seebacher C. Vulvovaginalkandidose. AWMF-Guideline 013/004 (S1) 2008
77. Mendling W, Spitzbart H. Antimykotische Therapie der vaginalen Hefepilz-Kolonisation von Schwangeren zur Verhütung von Kandidamykosen beim Neugeborenen. AMWF, Guideline 015/042 (S1) 2008.
78. Mendling W. Vaginose, Vaginitis, Zervizitis und Salpingitis. 2. Auflage, Springer Verlag Heidelberg 2006.
79. Meyer H, Göttlicher S, Mendling W. Stress as a cause of chronic recurrent vulvovaginal candidosis and the effectiveness of the conventional antimycotic therapy. Mycoses 2006; 48: 202-9.
80. Mendling W, Koldovsky U. Investigations by cell - mediated immunological tests of therapeutic trials with thymopentin in vaginal mycoses. Inf Dis Obstet Gynecol 1996; 4: 225-31.
81. Moraes PSA, de Lima Goiaba S, Taketoni EA. Candida albicans allergen immunotherapy in recurrent vaginal candidiasis. Invest Allergol Clin Immunol 2000; 10: 305-9.
82. Müller J, Nold B, Kubitza D, Baumert J. Quantitative Untersuchungen über die Döderlein - Flora gesunder sowie mykosekranker Probandinnen unter lokaler Isoconazo-Nitrat - Therapie. In: Seeliger HPR (ed) Gyno-Travogen-Monographie, Excerta Medica, Amsterdam Oxford Princeton 1981: 81-93.
83. Naglik J, Albrecht A, Bader O, Huber B. Candida albicans proteinases and host/pathogen interactions. Cellular Microbiology 2004; 6: 915-26.
84. Neves NA, Carvallho LP, de Oliveira MA, et al. Association between atopy and recurrent vaginal candidosis. Clin Exp Immunol 2005; 142: 167-71.
85. Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC, Hube B. Ciclopirox Olamine Treatment Affects the Expression Pattern of Metabolism Proteins, and Drug Resistance Factors. Antimicrob Agents Chemother 2003; 47: 1805-17.
86. Nurbhai M, Grimshaw J, Watson M, Bond C, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 2007: CD002845.
87. Nyirjesy P, Seeney SM, Grody MHT, Jordan CA, Buckeley HR. Chronic fungal vaginitis: The value of cultures. Am J Obstet Gynecol 1995; 173: 820-3.
88. Nyirjesy P, Alexander AB, Weitz MV. Vaginal candida parapsilosis: pathogen or bystander? Infect Dis Obstet Gynecol 2005; 13: 37-41.
89. Odds Fc. Candida and Candidosis, 2nd edn. England: Bailliére Tindall, WB Saunders, 1988.
90. Odds FC, Arai T, Disalvo AF, et al. Nomenclature of fungal diseases: a report and recommendations from a sub-Committee of the International Society for Human and Animal Mycology (ISHAM). J Med Vet Mycol 1992; 30: 1-10.
91. Paulitsch A, Weger W, Ginter-Hanselmayer G, Marth E, Buzina W. A 5-Year (2000 - 2004) epidemiological survey of Candida and non-Candida yeasts species causing vulvovaginal candidiasis in Graz, Austria. Mycoses 2006; 49: 471-5.
92. Phillips AJ. Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories. Am J Obstet Gynecol 2005; 192: 2009-12.
93. Pirotta MV, Gunn JM, Chondros P "Not thrush again" Women's experience of post-antibiotic vulvovaginitis. Med J Aust 2003; 179: 43-6.
94. Pirotta M, et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomized controlled trial. BMJ 2004; 329: 548-51.
95. Pirotta MV, Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Mecrobiol 2006; 44: 3213-7.
96. Pitsoni E, Lavazzo C, Falagas ME. Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomised controlled trials. Am J Obstet Gynecol. 2008; 198: 153-60.
97. Plempel M. Pharmakokinetik der Imidazol-Antimykotika. Mykosen 1980; 23: 16-27.
98. Powell BL. Identification of a 17 β-estradiol-binding protein in Candida albicans and Candida (Torulopsis) glabrata. Exp Mycology 1984; 8: 304.
99. Quereux C, Gelas B, Chevallier T, Petit F, Micheletti MC. Evaluation of the efficacy and speed of action of sertoconazole nitrate suppository and cream combined treatment for vulvovaginal candidiasis. Gynecol Obstet Fertil 2000; 28: 238-44.
100. Raska M, Belakova J, Horynova M, Krupka M, Novotny J, Sebestova M, Weigl E. Systemic and mucosal immunization with Candida albicans hsp 90 elicits hsp 90 specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis. Med Mycol 2008; 46: 411-20.
101. Ray D, Goswami R, Bomerjee U, et al. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007; 30: 312-7.
102. Reed BD, Zazone P, Pierson LL, Gorenflo DW, Horreocks J. Candida transmission and sexual behaviour as risk for a repeated episode of Candida vulvovaginitis. J Womens Health 2003; 12: 979-89.
103. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005; 42: 2155-62.
104. Rigg D, Miller MM, Metzger WJ. Recurrent allergic vulvo-vaginitis treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol 1990; 162: 332-6.
105. Ritter W. Pharmacokinetics of azole compounds. In: Berg D, Plempel M (eds), Sterol biosynthesis inhibitors. Ellis Horwood, Chichester 1988, pp 397-429.
106. Rosedale N, Browne K. Hyposensitation in the management of recurring vaginal candidiasis. Ann Allergy 1979; 43: 250-3.
107. Roth AC, Milsom I, Forssman L, Wáhlén P. Intermittend prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500mg clotrimazole vaginal tablet. Genitourin Med 1990; 66: 357-60.
108. Rüchel R, Fegeler R, Trost M. Comparison of secretory proteinases from different strains of Candida albicans. Sabouraudia 1982; 20: 233-44.
109. Rusch K, Schwiertz A. Candida autovaccination in the treatment of vulvovaginal Candida infections. Int J Gynecol Obstet 2007; 96: 130.
110. Savini V, Catavitello C, Manua A, Talia M, Febbo F, Balbinot A, d'Antonio D. Two cases of vaginitis caused by Itraconazole - resistant Saccharomyces cerevisiae and review of recently published studies. Mycopathologia 2008; 166: 47-50.
111. Scheklakow ND, Deletorski WW, Goldoa OA. Veränderungen der Ultrastruktur von Candida albicans unter Einwirkung von Polyen-Antibiotika. Mykosen 1980; 24: 140-52.
112. Schnell JD. Epidemiology and prevention of peripartal mycoses. Chemother 1982; 28(Suppl. I): 66-72.
113. Schnell JD, Voigt WH. Das Verhalten von Sprosspilzen am nicht verhornenden Plattenepithel. Arch Gynaekol 1974; 217: 377-82.
114. Singh S, Sobel JD, Bhargava P, Boikov D, Vasquez JA. Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Inf Dis 2002; 35: 1066-70.
115. Sobel JD. Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstet Gynecol 1985; 65: 435-40.
116. Sobel JD. Vaginitis due to Saccharomyces cereviseae: Epidemiology, clinical aspects, and therapy. Clin Inf Dis 1993; 16: 93-9.
117. Sobel JD. Vulvovaginitis due to Candida glabrata. An emerging problem. Mycoses 1998; 41(Suppl. 2): 18-21.
118. Sobel JD. Vulvovaginal candidosis. Lancet. 2007; 369: 1961-71.
119. Sobel JD, Harold C, Wiesenfeld MD, et al. Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis. N Engl J Med 2004; 351: 876-83.
120. Sobel JD, Myers PG, Kaye D, Leviston ME. Adherence of Candida albicans to human vaginal and buccal epithelial cells. J Infect Dis 1981; 143: 76-82.
121. Sobel JD, Zervos M, Reed BD, et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: Clinical implications. Antimicrob Agents Chemother 2003; 47: 34-8.
122. Sobel JD, Fisher J, Kauffman CA. Guidelines for the treatment of fungal urinary tract infections. In: Naber KG et al. (eds), Urogenital Infections. Europ Assoc Urol/Intern Consult Urol Dis 2010; Arnhem/Netherlands, pp 903-11.
123. Spacek J, Jilek P, Buchtav, Förstl M, Hronek M, Holeckova M. The serum levels of calcium, magnesium, iron and zinc in patients with recurrent vulvovaginal candidosis during attack, remission and in healthy controls. Mycoses 2005; 48: 391-5.
124. Spinillo A, Capuzzo E, Egbe TO, Baltaro P, Nicola S, Piazzi G. Torulopsis glabrata vaginitis. Obstet Gynecol 1995; 85: 993-8.
125. Tarry W, Fisher M, Shen S, Mawhinney M. Candida albicans: The estrogen target for vaginal colonization. J Surg Res 2005; 129: 278-82.
126. Thrumbore DJ, Sobel JD. Recurrent vulvovaginal candidiasis: vaginal epithelial cells susceptibility to Candida albicans adherence. Obstet Gynecol 1986; 67: 810-2.
127. Tietz HJ. Gezieltes Vorgehen gegen Problemkeime. Gyn Geburtsh 2009; 8: 41-4.
128. Tooley PJ. Patient and doctor preferences in the treatment of vaginal candidosis. Practitioner 1985; 229: 655-60.
129. Upmalis DH, Cone FL, Lamia CA, Reisman H, Rodriguez- Gomez G, Gilderman G, Bradley L. Single - dose miconazole nitrate vaginal ovule in the treatment of vulvovaginal candidiasis.: two single - blind, controlled studies versus miconazole nitrate 100mg cream for 7days. J Womens Health Gend Based Med 2000; 9: 421-9.
130. Wajnberg M, Wajnberg A. Doppelblind-Vergleichsstudie mit Ciclopyroxolamin- und Miconazol-Vaginalcreme bei vulvovaginaler Kandidose. Mykosen 1981; 24: 721-30.
131. Walker PP, Reynolds MT, Ashbee HR, Bown C, Evans FG. Vaginal Yeasts in the era of "over the counter" antifungals. Sex Transm Infect 2000; 76: 437-8.
132. Watson C, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole antifungal treatment of uncomplicated candidiasis (thrush): A systemic review. BJOG 2002; 109: 85-9.
133. Watson C, Calabretto H. Comprehensive review of conventional and non-conventional methods of managment of recurrent vulvovaginal candidiasis. Aust N Z J Obstet Gynecol 2007; 47: 262-72.
134. Weissenbacher TM, Witkin SS, Gingelmaier A, Scholz C, Friese K, Mylonas I. Relationship between recurrent vulvovaginal candidosis and immune mediators in vaginal fluid. Eur J Obstet Gynecol Reprod Biol 2009; 144: 59-63.
135. Wilson C. Recurrent vulvovaginal candidiasis; an overview of traditional and alternative therapies. Adv Nurse Pract. 2005; 13: 24-9.
136. Witkin SS, Jeremias J, Ledger WJ. A localized vaginal allergic response in women with recurrent vaginitis. J Allergy Clin Immunol 1988; 81: 412-6.
137. Witkin SS, Giraldo P, Linhares D. New insights into the immune pathogenesis of recurrent vulvovaginal candidiasis. Int J Gynecol Obestet 2000; 3: 114-8.
138. Wozniak KL, Palmer G, Kutner R, Fidel PL Jr. Immunotherapeutic approaches to enhance protective immunity against Candida vaginitis. Med Mycol. 2005; 43: 589-601.
139. Xu J, Schwartz K, Bartoces M, Monsur J, Severson RK, Sobel JD. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. J Am Board Fam Med 2008; 21: 261-8.
140. Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush in pregnancy) (review). The Cochrane Database of systematic Reviews 2001, Issue 4 Art No CD 000225. The Cochrane Collaboration. John Wiley & Sons, Ltd. 2005.